This ‘Ankylosing Spondylitis (AS)-Market Insights, Epidemiology, and Market Forecast-2030' report delivers an in-depth understanding of the AS, historical and forecasted epidemiology as well as the AS market trends in the United States.
The Ankylosing Spondylitis market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted AS market size from 2018 to 2030. The Report also covers current AS treatment practice, market drivers, market barriers, SWOT analysis, reimbursement and market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
- The United States
Study Period: 2018-2030
Ankylosing Spondylitis (AS) Disease Understanding and Treatment Algorithm
Ankylosing Spondylitis (AS) Overview
Ankylosing Spondylitis (AS) also called Bechterew's disease is a common inflammatory rheumatic disease that affects the axial skeleton, causing characteristic inflammatory back pain, which can lead to structural and functional impairments and a decrease in quality of life. Clinical features of this group include inflammatory back pain, asymmetrical peripheral oligoarthritis (predominantly of the lower limbs), enthesitis, and specific organ involvement such as anterior uveitis, psoriasis, and chronic inflammatory bowel disease. Aortic root involvement and conduction abnormalities are rare complications of AS. AS affects men more often than women.
General onset of AS commonly occurs in younger people, between the ages of 17 and 45. However, it can also affect children and those who are much older (Spondylitis association of america).AS is a type of spondyloarthropathy (SpA) - Spondyloarthropathies are a family of related inflammatory rheumatic disorders which also include reactive arthritis (RA), psoriatic arthritis (PsA), spondyloarthropathy associated with inflammatory bowel disease (IBD), undifferentiated spondyloarthropathy (USpA), and, possibly, Whipple disease and Behçet disease - and is often found in association with other spondyloarthropathies, including ReA, PsA, ulcerative colitis (UC), and Crohn disease. It has also been found that such patients quite often have a family history of either AS or another spondyloarthropathy.
Ankylosing Spondylitis (AS) Diagnosis
The most commonly used criteria for the classification of AS were developed in 1966 and modified in 1984. They are:
1. Low back pain of at least three months duration with inflammatory characteristics (improved by exercise, not relieved by rest)
2. Limitation of lumbar spine motion in sagittal and frontal planes
3. Decreased chest expansion (relative to normal values for age and sex)
4. Bilateral sacroiliitis grade 2 or higher
5. Unilateral sacroiliitis grade 3 or higher.
Definite AS is said to be present when the fourth or fifth criterion presents with any clinical criteria. However, radiological sacroiliitis may not develop for many years, and the development of new criteria (including magnetic resonance imaging) has been proposed to allow confirmation of the diagnosis in patients with early disease.
Ankylosing Spondylitis (AS) Treatment
Treatment of Ankylosing spondylitis will depend on the symptoms, age, and general health. It will also depend on how severe the condition is. The treatment goal is to reduce pain and stiffness, prevent deformities, and maintain as normal lifestyle as possible. Treatment may include: Nonsteroidal anti-inflammatory medications to reduce pain and inflammation, tumor-necrosis-factor blockers (biologic medications) to reduce inflammation and swelling, disease-modifying antirheumatic drugs (DMARDs) such as sulfasalazine to decrease inflammation and control AS, short-term use of corticosteroids to reduce inflammation, short-term use of muscle relaxants and pain relievers to relieve severe pain and muscle spasms, surgery to replace a joint, place rods in the spine, or remove parts of the thickened and hardened bone. Moreover, maintaining proper posture and regular exercise, including exercises that strengthen back muscles, is vital (Johns Hopkins Medicine, n.d.).
Ankylosing Spondylitis (AS) Epidemiology
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalence of Ankylosing Spondylitis, Diagnosed Prevalence of Ankylosing Spondylitis, Gender-specific Diagnosed Prevalence of Ankylosing Spondylitis, Age-specific Diagnosed Prevalence of Ankylosing Spondylitis, and Gene-specific Diagnosed Prevalence of Ankylosing Spondylitis scenario in the the United States from 2018 to 2030.
- The total prevalent population of Ankylosing Spondylitis (AS) in the US is anticipated to rise from 2018 to 2030. Out of the total prevalent population of 1,300,971 cases, 556,688 cases were diagnosed in 2020. These prevalent cases are expected to increase at a CAGR of 0.97% for the study period of 2018-2030.
- The prevalent population of Ankylosing Spondylitis (AS) showed a male predominance. Out of the total diagnosed population of 556,688 cases in the US, 389,681 and 167,006 cases were contributed by males and females, respectively, in 2020.
The diagnosis of Ankylosing Spondylitis can be tough to spot as so many people have back pain - its main symptom. Additionally, there are no specific lab tests to identify ankylosing spondylitis. All these factors play a major role in the low diagnosis of AS. Due to the increase in advancement, it is estimated that in the coming years, the diagnosis rate may increase.
Ankylosing Spondylitis (AS) Drug Chapters
Ankylosing Spondylitis (AS) Emerging Drugs
Tofacitinib (CP-690,550) is a Janus kinase inhibitor. In the signaling pathway, JAKs phosphorylate and activate Signal Transducers and Activators of Transcription (STATs), which modulate intracellular activity including gene expression. Tofacitinib modulates the signaling pathway at the point of JAKs, preventing the phosphorylation and activation of STATs. The drug is approved in the US for four indications: adults with moderately to severely active rheumatoid arthritis (RA) after methotrexate failure, adults with active psoriatic arthritis (PsA) after disease-modifying antirheumatic drug (DMARD) failure, adults with moderately to severely active ulcerative colitis (UC) after tumor necrosis factor inhibitor (TNFi) failure, and patients 2 years of age or older with active polyarticular course juvenile idiopathic arthritis (pcJIA).
Bimekizumab: UCB Biopharma
Bimekizumab (UCB4940) is the first humanized monoclonal IgG1 antibody that potently and selectively neutralizes IL-17A and IL-17F. These are the two key pro-inflammatory cytokines that share similar biological function and structural homology. IL-17A and IL-17F are the most closely related members of the IL-17 family of cytokines. They are both co-expressed at sites of inflammation and have overlapping pro-inflammatory functions. Both IL-17A and IL-17F can independently cooperate with other inflammatory mediators to drive chronic inflammation and tissue destruction. This therapeutic candidate is in the phase III stage of development to treat patients with Ankylosing Spondylitis (AS). The company is using the subcutaneous route of administration for AS.
Ankylosing Spondylitis (AS) Market Outlook
- Ankylosing spondylitis (AS) is an inflammatory disease that, over time, can cause some of the small bones in the spine (vertebrae) to fuse. This fusing makes the spine less flexible and can result in a hunched-forward posture. If ribs are affected, it can be difficult to breathe deeply. There is no cure for AS, but treatments can lessen your symptoms and possibly slow progression of the disease. Recent studies show that the newer biologic medications can potentially slow disease progression in some people. Different people respond to different medications with varying levels of effectiveness. Thus, it may take time to find the most effective course of treatment.
- A common treatment regimen for the various forms of spondyloarthritis (AS, psoriatic arthritis, enteropathic arthritis, reactive arthritis, juvenile spondyloarthritis, and undifferentiated spondyloarthritis) involves medication, exercise, physical therapy, good posture practices, and other options such as applying heat/cold to help relax muscles and reduce joint pain. In severe cases, posture correcting surgery may also be an option.
- Depending on the type of spondyloarthritis, there may be some variation in treatment. For example, in psoriatic arthritis, both the skin component and joint component must be treated. In enteropathic arthritis (spondylitis/arthritis associated with inflammatory bowel disease), medications may need to be adjusted so the gastrointestinal component of the disease is also treated and not exacerbated.
- As per the study conducted by Ward et al., (2019), recommendations for AS and nonradiographic axial SpA are similar. TNFi are recommended over secukinumab or ixekizumab as the first biologic to be used. Secukinumab or ixekizumab is recommended over the use of a second TNFi in patients with primary nonresponse to the first TNFi. TNFi, secukinumab, and ixekizumab are favored over tofacitinib. Co‐administration of low‐dose methotrexate with TNFi is not recommended, nor is a strict treat to target strategy or discontinuation or tapering of biologics in patients with stable disease. Sulfasalazine is recommended only for persistent peripheral arthritis when TNFi are contraindicated.
- Of the patients included in the study, 40.6% persisted on the index TNFi for ≥12 months, 31.0% discontinued, 21.4% switched to a different TNFi, and 7.0% discontinued and then restarted. Of the 333 patients who persisted on their TNFi for >90 days, 44.7% received ≥1 add-on medication. Approximately half of the patients (45.1%) initiated etanercept, followed by adalimumab (28.6%), golimumab (11.7%), infliximab (11.7%), and certolizumab pegol (2.8%) as their index TNFi was stated in a study conducted by Walsh et al., (2018).
- The total market size of Ankylosing Spondylitis (AS) in the US is anticipated to rise from 2018-2030. The total market size of Ankylosing Spondylitis (AS) in 2020 was estimated to be USD 3,366.93 million. The market size is expected to increase at a CAGR of 8.36% from 2018-2030.
- According to the analysis, for AS, the market of current treatment includes conventional therapies, biologics, and Cox Inhibitors.
- Among all the upcoming potential therapies, Bimekizumab is estimated to generate highest revenue. In its phase III clinical results, the molecule have shown the most effective result. At a dose of 160 mg, Efficacy response at week 96 in ASAS20 and ASAS40 was 76.9% and 64.6%, respectively, which is the highest as compared to all other therapies. Additionally, the Efficacy response at week 96 with shifting dose from 320mg to 160 mg in ASAS20 and ASAS40 was 79.8%, and 66.9%, respectively.
A common treatment regimen for AS, involves medication, exercise, physical therapy, good posture practices, and other options such as applying heat/cold to help relax muscles and reduce joint pain. There are several different classes of biologics such as Cox Inhibitors, JAK inhibitors, TNF inhibitors, IL-17 inhibitors, IL-12 and IL-23, and much more available in the market for the treatment.
Drugs such as Humira, Enbrel, Remicade, Rayos, and Celebrex entered the market earlier between the years 2000-2010. While some of the drugs were recently approved by the FDA, these drugs include Taltz, Cosentyx, and Simponi Aria while Cimzia was approved in the year 2013. Drugs like, Humira (Adalimumab), Remicade (Infliximab), and Celebrex (Celecoxib) have lost their patent in the US, in 2016, 2018, and 2014 respectively, and their generics have enetered the market as well. Although the entry of generic drugs has historically spelled doom for the reference product, biosimilars are not likely to play the same role in the marketplace, at least at first.
Due to these challenges, Remicade sales have not been substantially eroded by biosimilar competition just yet. Over the last 20 years, the greatly improved knowledges of underlying pathogenic mechanisms of AS, including the role of tumor necrosis factor (TNF), the interleukin 23/Th17 axis, and interleukin-17 (Il-17), constituted the rationale to develop biologics selectively inhibiting these pathways. Recent knowledge of the pathophysiology of spondyloarthritis has highlighted the emerging role of the IL-17/IL-23 axis.
New therapies with selective biological drugs have emerged in the treatment of this pathology. Recently, the approval of Taltz (ixekizumab) - a new anti-IL-17A - for the treatment of ankylosing spondylitis, is anticipated to show positive growth in the market. The pipeline therapies belonging to IL-17A are estimated to generate a good market share due to their effectiveness and potential.”
The United States Market Outlook
This section provides the total AS market size and market size by therapies & class in the United States.
Ankylosing Spondylitis (AS) Drugs Uptake
This section focuses on the rate of uptake of the potential drugs recently launched in the AS market or expected to get launched in the market during the study period 2018-2030. The analysis covers the AS market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Ankylosing Spondylitis (AS) Development Activities
The report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for AS emerging therapies.
Reimbursement Scenario in Ankylosing Spondylitis (AS).
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, the publisher considers reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
Competitive Intelligence Analysis
The publisher performs competitive and market Intelligence analysis of the AS market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Scope of the Report
- The report covers the descriptive overview of AS, explaining its causes, symptoms, pathophysiology, genetic basis, and currently available therapies.
- Comprehensive insight has been provided into the AS epidemiology and treatment.
- Additionally, an all-inclusive account of both the current and emerging therapies for AS is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
- A detailed review of the AS market; historical and forecasted is included in the report, covering the United States drug outreach.
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the United States AS market.
- The robust pipeline with novel MOA and oral ROA, increasing incidence, effectiveness of drugs as both mono and combination therapy will positively drive the AS market.
- The companies and academics are working to assess challenges and seek opportunities that could influence AS R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- Major players are involved in developing therapies for AS. The launch of emerging therapies will significantly impact the AS market.
- This in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross competition, launch date along product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Ankylosing Spondylitis (AS) Report Insights
- Patient Population
- Therapeutic Approaches
- AS Pipeline Analysis
- AS Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
Ankylosing Spondylitis (AS) Report Key Strengths
- 10 Years Forecast
- United States Coverage
- AS Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Market
- Drugs Uptake
Ankylosing Spondylitis (AS) Report Assessment
- Current Treatment Practices
- Unmet Needs
- Pipeline Product Profiles
- Market Attractiveness
- Market Drivers and Barriers
- SWOT analysis
Key Questions Answered:
- What was the AS market share (%) distribution in 2018 and how it would look like in 2030?
- What would be the AS total market size as well as market size by therapies across the United States during the forecast period (2021-2030)?
- What are the key findings pertaining to the market across the United States and which country will have the largest AS market size during the forecast period (2021-2030)?
- At what CAGR, the AS market is expected to grow at the United States level during the forecast period (2021-2030)?
- What would be the AS market outlook across the United States during the forecast period (2021-2030)?
- What would be the AS market growth till 2030 and what will be the resultant market size in the year 2030?
- How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
- What are the disease risk, burdens, and unmet needs of AS?
- What is the historical AS patient pool in the United States?
- What would be the forecasted patient pool of AS at the United States level?
- What will be the growth opportunities across the United States with respect to the patient population pertaining to AS?
- At what CAGR the population is expected to grow across the United States during the forecast period (2021-2030)?
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:
- What are the current options for the treatment of AS along with the approved therapy?
- What are the current treatment guidelines for the treatment of AS in the US?
- What are the AS marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
- How many companies are developing therapies for the treatment of AS?
- How many emerging therapies are in the mid-stage and late stages of development for the treatment of AS?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the AS therapies?
- What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for AS and their status?
- What are the key designations that have been granted for the emerging therapies for AS?
- What is the United States historical and forecasted market of AS?
Reasons to Buy
- The report will help in developing business strategies by understanding trends shaping and driving AS.
- To understand the future market competition in the AS market and Insightful review of the key market drivers and barriers.
- Organize sales and marketing efforts by identifying the best opportunities for AS in the US.
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
- Organize sales and marketing efforts by identifying the best opportunities for the AS market.
- To understand the future market competition in the AS market.
1 Key Insights
2 Executive Summary of Ankylosing Spondylitis (AS)
3 Disease Background and Overview: Ankylosing Spondylitis (AS)
3.2 Severity based classification
3.2.1 Mild or early ankylosing spondylitis:
3.2.2 Severe or advanced AS:
3.3 Biology and pathology of AS
3.4.1 Endogenous Factors
3.4.2 Exogenous Factors
3.5 Risk Factors of AS
3.5.2 Family History
3.5.3 Genetic Predisposition
3.6 Signs and symptoms of AS
3.7 Genetics of ankylosing spondylitis - insights into pathogenesis
3.7.1 HLAB27 causing AS:
3.7.2 Antigen processing and presentation:
3.7.3 IL-17 and type 3 immunity in AS:
188.8.131.52 γδ T cells:
184.108.40.206 KIR3DL2+ T cells:
220.127.116.11 NKT cells:
18.104.22.168 Mast cells and neutrophils:
22.214.171.124 CD4 and CD8 T-cells:
3.7.5 IL-23 signaling:
3.7.6 Targeting type-3 immunity in AS:
3.8.1 Genetic biomarkers
3.8.2 Markers for inflammation
3.8.3 Cartilage Turnover Markers
3.8.4 Other Biomarkers
3.9.3 Laboratory Findings
3.9.5 Osteoporosis and Fracture
3.9.7 Mobility Testing
3.9.8 Strength Testing
3.9.9 Spine examination
3.1 Diagnostic Criteria
3.10.1 New York Classification Criteria: Diagnostic Criteria
4 Case Reports
4.1 Spinal subdural hematoma and ankylosing spondylitis: Case report and review of literature
4.2 Oral rehabilitation of a patient with ankylosing spondylitis and orofacial pain: A case report
5 Patient Journey
6 Epidemiology and Patient Population
6.1 KOL Views
6.2 Epidemiology Methodology
6.3 United States
6.3.1 Assumptions and Rationale
6.3.2 Total Prevalence of Ankylosing Spondylitis in the United States
6.3.3 Diagnosed Prevalence of Ankylosing Spondylitis in the United States
6.3.4 Gender-specific Diagnosed Prevalence of Ankylosing spondylitis in the United States
6.3.5 Age-specific Diagnosed Prevalence of Ankylosing spondylitis in the United States
6.3.6 Gene-specific Diagnosed Prevalence of Ankylosing Spondylitis in the United States
7 Current Treatment and Medical Practices
7.3 Lifestyle and home remedies
7.4 General Principles of Management
7.5 Treatment algorithm
7.6 Treatment Guidelines
7.6.1 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of AS and Nonradiographic Axial Spondyloarthritis
8 Unmet needs
9 Marketed drugs
9.1 Key cross competition- Marketed drugs
9.2 Cimzia (Certolizumab pegol): UCB
9.2.1 Drug Description
9.2.2 Regulatory Milestones
9.2.3 Other Developmental Activities
9.2.4 Clinical Development
126.96.36.199 Clinical Trials Information
9.2.5 Safety and Efficacy
9.2.6 Product Profile
9.3 Humira (adalimumab): AbbVie
9.3.1 Drug Description
9.3.2 Regulatory Milestones
9.3.3 Other Developmental Activities
9.3.4 Clinical Development
188.8.131.52 Clinical Trials Information
9.3.5 Safety and Efficacy
9.3.6 Product Profile
9.4 Celebrex (celecoxib): Pfizer
9.4.1 Drug Description
9.4.2 Regulatory Milestones
9.4.3 Other Developmental Activities
9.4.4 Clinical Development
184.108.40.206 Clinical Trials Information
9.4.5 Safety and Efficacy
9.4.6 Product Profile
9.5 Enbrel (Etanercept): Amgen/Pfizer
9.5.1 Drug Description
9.5.2 Regulatory Milestones
9.5.3 Other Developmental Activities
9.5.4 Clinical Development
220.127.116.11 Clinical Trials Information
9.5.5 Safety and Efficacy
9.5.6 Product Profile
9.6 Remicade (Infliximab): Janssen Biotech
9.6.1 Drug Description
9.6.2 Regulatory Milestones
9.6.3 Other Developmental Activities
9.6.4 Clinical Development
18.104.22.168 Clinical Trials Information
9.6.5 Safety and Efficacy
9.6.6 Product Profile
9.7 Simponi (Golimumab): Janssen Biotech
9.7.1 Drug Description
9.7.2 Regulatory Milestones
9.7.3 Other Developmental Activities
9.7.4 Clinical Development
22.214.171.124 Clinical Trials Information
9.7.5 Safety and Efficacy
9.7.6 Product Profile
9.8 Vimovo (naproxen and esomeprazole magnesium): Pozen
9.8.1 Drug Description
9.8.2 Regulatory Milestones
9.8.3 Other Developmental Activities
9.8.4 Clinical Development
126.96.36.199 Clinical Trials Information
9.8.5 Safety and Efficacy
9.8.6 Product Profile
9.9 Cosentyx: Novartis
9.9.1 Drug Description
9.9.2 Regulatory Milestones
9.9.3 Other Developmental Activities
9.9.4 Clinical Development
188.8.131.52 Clinical Trials Information
9.9.5 Safety and Efficacy
9.9.6 Product Profile
9.10 Indocin: Iroko Pharmaceuticals
9.10.1 Drug Description
9.10.2 Safety and Efficacy
9.10.3 Product Profile
9.11 Naprelan: Syntex Pharmaceuticals
9.11.1 Drug Description
9.11.2 Other Developmental Activities
9.11.3 Product Profile
9.12 Rayos (Prednisone): Horizon Pharma
9.12.1 Drug Description
9.12.2 Regulatory Milestones
9.12.3 Other Developmental Activities
9.12.4 Product Profile
9.13 Taltz (ixekizumab): Eli Lilly and Company
9.13.1 Drug Description
9.13.2 Regulatory Milestones
9.13.3 Other Development Activities
9.13.4 Clinical Development
184.108.40.206 Clinical Trials Information
9.13.5 Safety and Efficacy
9.13.6 Product Profile
10 Emerging Therapies
10.1 Key cross competition- Emerging Therapies
10.2 Tofacitinib: Pfizer
10.2.1 Product Description
10.2.2 Other Developmental Activities
10.2.3 Clinical Development
10.2.3.1 Clinical Trials Information
10.2.4 Safety and Efficacy
10.2.5 Product Profile
10.3 Bimekizumab: UCB Biopharma
10.3.1 Product Description
10.3.2 Other Developmental Activities
10.3.3 Clinical Development
10.3.3.1 Clinical Trials Information
10.3.4 Safety and Efficacy
10.3.5 Product Profile
10.5 Ilumya (Tildrakizumab): Sun Pharma Global
10.5.1 Product Description
10.5.2 Other Developmental Activities
10.5.3 Clinical Development
10.5.3.1 Clinical Trials Information
10.5.4 Product Profile
10.6 Namilumab: Izana Bioscience
10.6.1 Product Description
10.6.2 Other Developmental Activities
10.6.3 Clinical Development
10.6.3.1 Clinical Trials Information
10.6.4 Product Profile
10.7 ILT-101(Interleukin 2): Iltoo Pharma
10.7.1 Product Description
10.7.2 Other Developmental Activities
10.7.3 Clinical Development
10.7.3.1 Clinical Trials Information
10.7.4 Safety and Efficacy
10.7.5 Product Profile
10.8 Brodalumab (KHK4827): Kyowa Kirin
10.8.1 Product Description
10.8.2 Other Developmental Activities
10.8.3 Clinical Development
10.8.3.1 Clinical Trials Information
10.8.4 Safety and Efficacy
10.8.5 Product Profile
10.9 Rinvoq (Upadacitinib): Abbvie
10.9.1 Product Description
10.9.2 Other Developmental Activities
10.9.3 Clinical Development
10.9.3.1 Clinical Trials Information
10.9.4 Safety and Efficacy
10.9.5 Product Profile
11 Failed Therapies
11.1 Filgotinib: Galapagos/Gilead
11.1.1 Product Description
11.1.2 Other Developmental Activities
11.1.3 Clinical Development
220.127.116.11 Clinical Trials Information
11.1.4 Safety and Efficacy
11.1.5 Product Profile
12 Potential of Emerging Therapies and Current therapies
13 Attribute Analysis
14 Key Market Forecast Assumptions
15 Market Methodology
16 Ankylosing Spondylitis (AS): United States Market Outlook
16.1 United States Market Size
16.1.1 The total market size of Ankylosing Spondylitis
16.1.2 Market Size of Ankylosing Spondylitis by therapies
18.104.22.168 Market Size of Ankylosing Spondylitis by Class
17 Market Drivers
18 Market Barriers
19 SWOT Analysis
20 Reimbursement and Market access
21.2 Report Methodology
22 Publisher Capabilities
24 About the Publisher
List of Tables
Table 1: Summary of Ankylosing Spondylitis (AS), Market, Epidemiology, and Key Events (2018-2030)
Table 2: Genetic Associations with AS
Table 3: Total Prevalence of Ankylosing Spondylitis in the United States (2018-2030)
Table 4: Diagnosed Prevalence of Ankylosing Spondylitis in the United States (2018-2030)
Table 5: Gender-specific Diagnosed Prevalence of Ankylosing Spondylitis in the United States (2018-2030)
Table 6: Age-specific Diagnosed Prevalence of Ankylosing Spondylitis in the United States (2018-2030)
Table 7: Gene-specific Diagnosed Prevalence of Ankylosing Spondylitis in the United States (2018-2030)
Table 8: Principles of Management of AS
Table 9: Treatment Network Recommendations for the Treatment of AS and Nonradiographic Axial Spondyloarthritis
Table 10: Key cross competition- Marketed drugs
Table 11: Cimzia (certolizumab pegol), Clinical Trial Description, 2021
Table 12: Humira (adalimumab), Clinical Trial Description, 2021
Table 13: Celebrex (celecoxib), Clinical Trial Description, 2021
Table 14: Enbrel (Etanercept), Clinical Trial Description, 2021
Table 15: Remicade (Infliximab), Clinical Trial Description, 2021
Table 16: Simponi (Golimumab), Clinical Trial Description, 2021
Table 17: Vimovo (Esomeprazole/naproxen), Clinical Trial Description, 2021
Table 18: Cosentyx (secukinumab), Clinical Trial Description, 2021
Table 19: Taltz (ixekizumab), Clinical Trial Description, 2021
Table 20: Key cross competition- Emerging Therapies
Table 21: Tofacitinib, Clinical Trial Description, 2021
Table 22: Bimekizumab, Clinical Trial Description, 2021
Table 23: Filgotinib, Clinical Trial Description, 2021
Table 24: Tildrakizumab, Clinical Trial Description, 2021
Table 25: Namilumab, Clinical Trial Description, 2021
Table 26: ILT-101, Clinical Trial Description, 2021
Table 27: KHK4827, Clinical Trial Description, 2021
Table 28: Upadacitinib, Clinical Trial Description, 2021
Table 29: Key market forecast assumptions for Bimekizumab
Table 30: Key market forecast assumptions for Rinvoq
Table 31: Key market forecast assumptions for Brodalumab
Table 32: Key market forecast assumptions for Tofacitinib
Table 33: Key market forecast assumptions for Taltz
Table 34: United States Market Size of Ankylosing Spondylitis in USD Million (2018-2030)
Table 35: Market Size of Ankylosing Spondylitis by therapies in the US, in USD Million (2018-2030)
Table 36: Market Size of Ankylosing Spondylitis by Class in the US, in USD Million (2018-2030)
List of Figures
Figure 1: Possible Complications of Ankylosing Spondylitis
Figure 2: Pathology of entheses in AS
Figure 3: Risk Factors for Ankylosing Spondylitis
Figure 4: Functional roles of AS-associated genes
Figure 5: Antigen processing and presentation: potential link to AS
Figure 6: Multiple roles for HLA-B27 in the pathogenesis of Ankylosing spondylitis
Figure 7: Immune cells involved in the initiation, progression, and regulation of AS
Figure 8: The role of the gut in driving joint inflammation in ankylosing spondylitis
Figure 9: Potential mechanisms by which ERAP variants operate to influence disease risk in ankylosing spondylitis
Figure 10: ASAS classification criteria for axial and peripheral spondyloarthritis
Figure 11: Total Prevalence of Ankylosing Spondylitis in the United States (2018-2030)
Figure 12: Diagnosed Prevalence of Ankylosing Spondylitis in the United States (2018-2030)
Figure 13: Gender-specific Diagnosed Prevalence of Ankylosing Spondylitis in the United States (2018-2030)
Figure 14: Age-specific Diagnosed Prevalence of Ankylosing Spondylitis in the United States (2018-2030)
Figure 15: Gene-specific Diagnosed Prevalence of Ankylosing Spondylitis in the United States (2018-2030)
Figure 16: Treatment Algorithm of AS
Figure 17: Summary of the main recommendations
Figure 18: Market Size of Ankylosing Spondylitis in the United States, in USD Millions (2018-2030)
Figure 19: Market Size of Ankylosing Spondylitis by therapies in the US, in USD Millions (2018-2030)
Figure 20: Market Size of Ankylosing Spondylitis by Class in the US, in USD Millions (2018-2030)
Figure 21: Market Barriers
Figure 22: SWOT Analysis of Ankylosing spondylitis